Nephrology & Urology CME/CE Courses & Articles

CME

Nephrology and Urology CME/CE Courses

myCMEYour search for high-quality, complimentary CME/CE stops right here. The courses below are presented by myCME, the continuing education engine in Haymarket Medical Network’s (HMN) expanding portfolio of clinical websites. Below you’ll find practice-relevant courses that carry valuable CME/CE credit. Simply click any link to get started earning credit on myCME.

Featured Courses

Renal Cell Carcinoma: Advances Across the Treatment Continuum

Renal Cell Carcinoma: Advances Across the Treatment Continuum | myCME

AMA PRA Category 1 Credit(s)TM
Create your own slide deck on renal cell carcinoma (RCC) with this comprehensive slide repository on therapy selection and recent clinical advances in treatment. Slides are imbedded with expert commentary from MD Anderson, Memorial Sloan Kettering, Dana-Farber, and Vanderbilt faculty.
Metastatic Hormone-Sensitive Prostate Cancer: Benefits and Risks of Current and Emerging Treatment Options

mHSPC: Treatment Benefits and Risks | myCME

AMA PRA Category 1 Credit(s)TM
In this Clinical Callout activity, you will be presented with patient vignettes that highlight symptoms, risk factors, medical histories, and other considerations that potentially influence the course of treatment and monitoring of patients with CLL and MCL. Your challenge is to choose the most appropriate next step from several possible clinical strategies, but be careful: only one option reflects current best practice!
Assessment and Management of Hyperkalemia in the Hospital Setting: Optimizing Patient Outcomes

Assessment and Management of Hyperkalemia in the Hospital Setting

AMA PRA Category 1 Credit(s)TM, CNE Contact Hour(s), CE for Pharmacists
The risk of hyperkalemia increases significantly for patients with chronic kidney disease (CKD) and for those who take common medications for heart failure (HF), such as RAAS inhibitors, which can increase potassium in the blood. Hyperkalemia occurs in 23% to 47% of patients with CKD and/or HF, with an estimated 200 million and 38 million people, respectively, living with each condition worldwide. If not treated rapidly, severe hyperkalemia may lead to cardiac arrest and death.
Examining the Use of Newer and Emerging Agents in Bladder Cancer: What Clinicians Need to Know

Examining Newer and Emerging Agents in Bladder Cancer | myCME

AMA PRA Category 1 Credit(s)TM
This activity features several relevant bladder cancer case discussions that have been cultivated by the expert faculty and will include an examination of the evolving role of checkpoint inhibition across various stages of the bladder cancer disease continuum, with particular emphasis on novel approaches in advanced disease.
Dietary Considerations for Patients With ADPKD

Dietary Considerations for Patients With ADPKD | myCME

AMA PRA Category 1 Credit(s)TM, CPEU Credit
Dietary changes are recommended for patients with autosomal-dominant polycystic kidney disease (ADPKD) and especially for ADPKD patients being treated with tolvaptan, a vasopressin inhibitor. Dietitians need to use effective communication strategies to encourage patients to make lifetime changes in their dietary habits.
The Role of Immune Checkpoint Inhibitors in the Treatment of Genitourinary Cancers: An Interprofessional Perspective on Guideline Updates

The Role of Immune Checkpoint Inhibitors in the Treatment of Genitourinary Cancers: An Interprofessional Perspective on Guideline Updates | myCME

ANCC Contact Hour(s)
The landscape of genitourinary cancer therapy is evolving. As treatment options expand and are integrated into treatment regimens, and guidelines are updated to reflect these advances, there is an ongoing need for the members of the care team to engage in continuing education in this area. Additionally, as the pandemic continues, it’s important that clinicians recognize and apply strategies for reducing the risk of COVID-19 infection in vulnerable patients.
Early Identification of ADPKD: Slowing Progression

Early Identification of ADPKD: Slowing Progression | myCME

AMA PRA Category 1 Credit(s)TM, CPEU Credit
Treatment of autosomal-dominant polycystic kidney disease (ADPKD) has changed with the approval of tolvaptan, a vasopressin inhibitor that can slow progression of the disease. Primary care providers need to be aware of ADPKD and learn to diagnose it so their patients can receive early treatment that can delay kidney impairment and failure.
Current ADPKD Treatment: Slow Progression and Improve Outcomes

Current ADPKD Treatment: Slow Progression and Improve Outcomes | myCME

AMA PRA Category 1 Credit(s)TM, CPEU Credit
The management of autosomal-dominant polycystic kidney disease (ADPKD) changed dramatically with the approval of tolvaptan as a novel therapy that can slow the progression of cyst development and renal insufficiency in patients at risk of rapidly progressing ADPKD.
The Critical Role of APPs in the Success of Minimally Invasive Approaches for BPH

The Critical Role of APPs in the Success of Minimally Invasive Approaches for BPH | myCME

AMA PRA Category 1 Credit(s)TM, CNE Contact Hour(s)
An increase in the aging population in the United States in the next few years is expected to create high demand for BPH treatments. Prostatic urethral lift, an AUA recommended noninvasive approach, may be an alternative option for patients with lower urinary tract symptoms and provides another tool in the armamentarium for treating BPH.

Click for More Renal and Urology Courses

Next post in CME Articles